Spanish Society of Medical Oncology consensus for the use of haematopoietic colony-stimulating factors in cancer patients
详细信息 查看全文
- 作者：Alfredo Carrato Mena (1) (2)
Luis Paz-Ares Rodríguez (3)
álvaro Rodríguez Lescure (4)
Ana M. Casas Fernández de Tejerina (3)
Eduardo Díaz Rubio García (5)
Pedro Pérez Segura (5)
Manuel Constenla Figueiras (6)
Rocío García Carbonero (7)
José Gómez Codina (8)
Ana Lluch Hernández (9)
José Pablo Maroto Rey (10)
Miguel Martín Jiménez (5)
José Ignacio Mayordomo Cámara (11)
José Andrés Moreno Nogueira (3)
Antonio Rueda Domínguez (12) - 关键词：Colony ; stimulating factors ; Neutropenia ; Febrile neutropenia ; Chemotherapy ; Consensus
- 刊名：Clinical and Translational Oncology
- 出版年：2009
- 出版时间：July 2009
- 年：2009
- 卷：11
- 期：7
- 页码：446-454
- 全文大小：484KB
- 参考文献：1. Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106:2258-266 CrossRef
2. Caggiano V, Weiss RV, Rickert TS, Linde-Zwirble WT (2005) Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy. Cancer 103:1916-924 CrossRef
3. Mayordomo JI, López A, Vi?olas N et al on behalf of the ENIA Study Group (2006) Cost of febrile neutropenia management in cancer patients in Spain. J Clin Oncol 24[June 20 Suppl]:6089
4. Lyman GH, Kuderer NM, Djulbegovic B (2002) Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 112:406-11 CrossRef
5. Kuderer NM, Dale DC, Crawford J, Lyman GH (2007) Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 25:3158-167 CrossRef
6. Smith TJ, Khatcheressian J, Lyman GH et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24:3187-205 CrossRef
7. Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicentre, double-blind, placebo controlled phase III study. J Clin Oncol 23:1178-184 CrossRef
8. Timmer-Bonte JN, de Boo TM, Smit HJ (2005) Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in smallcell lung cancer: a Dutch Randomized Phase III Study. J Clin Oncol 23:7974-984 CrossRef
9. Crawford J, Althaus B, Armitage J et al (2007) Myeloid growth factors. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 5:188-02
10. Aapro MS, Cameron DA, Pettengell R (2006) EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42:2433-453 CrossRef
11. Escobar Rodriguez I, Sevilla Azzati E, Rodríguez Sagrero MA et al (1998) Estudio multicéntrico de utilización de factores estimulantes de crecimiento hematopoyético. Farm Hosp 22:109-25
12. Scott SD, Chrischilles EA, Link BK et al (2003) Days of prophylactic filgrastim use to reduce febrile neutropenia in patients with non-Hodgkin’s lymphoma treated with chemotherapy. J Manag Care Pharm 9[2 Suppl]:15-1
13. Almenar D, Mayans J, Juan O et al (2005) Pegfilgrastim and daily granulocyte colony-stimulating factor (G-CSF). Patterns of use and neutropeniarelated outcomes in cancer patients in Spain: results of the Learn Study. Blood 106[Suppl]: Abstract 4263
14. Lyman GH, Kuderer NM (2003) Epidemiology of febrile neutropenia. Supp Cancer Ther 1:23-5 CrossRef
15. Crawford J, Dale DC, Lyman GH (2004) Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100:228-37 CrossRef
16. Greil R, Jost LM (2005) ESMO recommendations for the application of hematopoietic growth factors. ESMO Guidelines Task Force. Ann Oncol 16[Suppl 1]:i80–i82
17. Bunn PA Jr, Crowley J, Kelly K et al (1995) Chemoradiotherapy with or without granulocytemacrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group. J Clin Oncol 13: 1632-641
18. Balducci L (2003) New paradigms for treating elderly patients with cancer: the comprehensive geriatric assessment and guidelines for supportive care. J Support Oncol 1[4 Suppl 2]:30-7
19. Balduci L, Carreca I (2002) The role of myelopoietic growth factors in managing cancer in the elderly. Drugs 62:47-3 CrossRef
20. Repetto L (2003) Greater risks of chemotherapy toxicity in elderly patients with cancer J Supp Oncol 4:18-4
21. Lichtman SM, Skirvin JA, Vemulapalli S (2003) Pharmacology of antineoplastic agents in older cancer patients. Crit Rev Oncol Hematol 46:101-14 CrossRef
22. Dale DC (2003) Poor prognosis in elderly patients with cancer: the role of bias and undertreatment. J Support Oncol 1[4 Suppl 2]:11-7
23. Balducci L, Extermann M (2005) Management of cancer in the older person: a practical approach. Oncologist 5:224-37 CrossRef
24. Balducci L, Extermann M (2000) Cancer and aging. An evolving panorama. Hematol Oncol Clin North Am 14:1-6 CrossRef
25. Bower M, McCall-Peat N, Ryan N et al (2004) Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 104:2943-946 CrossRef
26. Harbol AW, Liesveld JL, Simpson-Haidaris PJ, Abboud CN (1994) Mechanisms of cytopenia in human immunodeficiency virus infection. Blood Rev 8:241-51 CrossRef
27. Norton L, Simon R (1986) The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163-69
28. Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/ Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21:1431-439 CrossRef
29. Pfreundschuh M, Trümper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 104:634-41 CrossRef
30. Pfreundschuh M, Trümper L, Kloess M et al (2004) Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 104:626-33 CrossRef
31. Pfreundschuh M, Trümper L, Kloess M et al (2005) Six, not eight cycles of bi-weekly CHOP with rituximab (R-CHOP 14) is the preferred treatment for elderly patients with diffuse large-B-cell lymphoma: results of the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 106:abstract 13
32. Kloess M, Zeynalova S, Trümper L et al (2003) Effects of G-CSF scheduled on leucocyte recovery and infection rate in the CHOP-14 regimen for elderly patients with aggressive lymphoma. Proc Am Soc Clin Oncol 22:597 [abstract 2402]
33. Holmes FA, O’shaughnessy JA, Vukelja S (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20:727-31 CrossRef
34. Siena S, Piccart MJ, Holmes FA et al (2003) A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep 10:715-24
35. Wolf M, Bentley M, Marlton P et al (2006) Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin’s lymphoma. Leuk Lymphoma 47:2344-350 CrossRef
36. Schneeweiss A, Schuetz F, Rudlowski C et al (2005) Dose-dense primary systemic chemotherapy with gemcitabine plus epirubicin sequentially followed by docetaxel for early breast cancer: final results of a phase I/II trial. Anticancer Drugs 16:1023-028 CrossRef
37. Burstein HJ, Parker LM, Keshaviah A et al (2005) Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol 23:8340-347 CrossRef
38. López A, Fernández de Sevilla A, Castaigne S et al (2004) Pegfilgrastim supports delivery of CHOP-R chemotherapy administered every 14 days: a randomised phase II study. Blood 103:abstract 3311
39. Engert A, Bredenfeld H, D?hner H et al (2006) Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with highrisk Hodgkin’s lymphoma: results of a phase II study. Haematologica 91:546-49
40. Gabrilove JL, Jakubowski A, Scher H et al (1988) Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 318:1414-422
41. Martín M, Lluch A, Seguí MA et al (2006) Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocytecolony stimulating factor to the TAC regimen. Ann Oncol 17:1205-212 CrossRef
42. Green MD, Koelbl H, Baselga J et al (2003) International Pegfilgrastim 749 Study Group. A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14:29-5 CrossRef
43. Juttner CA, To LB, Haylock DN et al (1985) Circulating autologous stem cells collected in very early remission from acute non-lymphoblastic leukaemia produce prompt but incomplete haemopoietic reconstitution after high dose melphalan or supralethal chemoradiotherapy. Br J Haematol 61:739-45 CrossRef
44. Liu KY, Akashi K, Harada M et al (1993) Kinetics of circulating haematopoietic progenitors during chemotherapy-induced mobilization with or without granulocyte colony-stimulating factor. Br J Haematol 84:31-8 CrossRef
45. Weaver CH, Schulman KA, Wilson-Relyea B et al (2000) Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells. J Clin Oncol 18:43-3
46. Facon T, Harousseau JL, Maloisel F et al (1999) Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 94:1218-225
47. Bruns I, Steidl U, Kronenwett R et al (2006) A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma. Transfusion 46:180-85 CrossRef
48. Isidori A, Tani M, Bonifazi F et al (2005) Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients. Haematologica 90:225-31
49. Prósper F, Solá C, Hornedo J et al (2003) Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy. Leukemia 17:437-41 CrossRef
50. Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316-22
51. Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038-051
52. Gerhartz HH, Stern AC, Wolf-Hornung B et al (1993) Intervention treatment of established neutropenia with human recombinant granulocytemacrophage colony-stimulating factor (rhGMCSF) in patients undergoing cancer chemotherapy. Leuk Res 17:175-85 CrossRef
53. Soda H, Oka M, Fukuda M et al (1996) Optimal schedule for administering granulocyte colonystimulating factor in chemotherapy-induced neutropenia in non-small-cell lung cancer. Cancer Chemother Pharmacol 38:9-2 CrossRef
54. Hartmann LC, Tschetter LK, Habermann TM et al (1997) Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. N Engl J Med 336:1776-780 CrossRef
55. Lyman GH, Lyman CG, Sanderson RA, Balducci L (1993) Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488-93 CrossRef
56. Garcia-Carbonero R, Paz-Ares L (2002) Antibiotics and growth factors in the management of fever and neutropenia in cancer patients. Curr Opin Hematol 9:215-21 CrossRef
57. Berghmans T, Paesmans M, Lafitte JJ et al (2002) Therapeutic use of granulocyte and granulocytemacrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 10:181-88 CrossRef
58. Clark OA, Lyman G, Castro AA et al (2003) Colony stimulating factors for chemotherapy induced febrile neutropenia. Cochrane Database Syst Rev (3):CD003039
59. Clark OA, Lyman GH, Castro AA et al (2005) Colony-stimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol 23:4198-214 CrossRef
60. Biesma B, de Vries EG, Willemse PH (1990) Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever. Eur J Cancer 26:932-36 CrossRef
61. Maher DW, Lieschke GJ, Green M (1994) Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 121:492-01 - 作者单位：Alfredo Carrato Mena (1) (2)
Luis Paz-Ares Rodríguez (3)
álvaro Rodríguez Lescure (4)
Ana M. Casas Fernández de Tejerina (3)
Eduardo Díaz Rubio García (5)
Pedro Pérez Segura (5)
Manuel Constenla Figueiras (6)
Rocío García Carbonero (7)
José Gómez Codina (8)
Ana Lluch Hernández (9)
José Pablo Maroto Rey (10)
Miguel Martín Jiménez (5)
José Ignacio Mayordomo Cámara (11)
José Andrés Moreno Nogueira (3)
Antonio Rueda Domínguez (12)
1. Medical Oncology Department, Ramón y Cajal University Hospital, Ctra. de Colmenar Viejo, km. 9,100, ES-28034, Madrid, Spain
2. Hospital Universitario Ramón y Cajal, Madrid, Spain
3. Hospital Virgen del Rocío, Sevilla, Spain
4. Hospital General Universitario de Elche, Elche, Spain
5. Hospital Clínico Universitario San Carlos, Madrid, Spain
6. Complejo Hospitalario de Pontevedra, Pontevedra, Spain
7. Hospital Severo Ochoa, Leganés, Madrid, Spain
8. Hospital Universitario La Fe, Valencia, Spain
9. Hospital Clínico Universitario de Valencia, Valencia, Spain
10. Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
11. Hospital Clínico Universitario, Lozano Blesa, Zaragoza, Spain
12. Hospital Virgen de la Victoria, Málaga, Spain
文摘
Neutropenia is a common complication of cancer chemotherapy. Colony-stimulating factors (CSF) may be used to avoid neutropenia-associated complications. The Spanish Society of Medical Oncology (SEOM) recently constituted a working group to review the main issues concerning the use of CSF and carried out a consensus process about the use of CSF in cancer patients, held in Madrid on 26 May 2006. The group concluded the following recommendations: prophylactic use of CSF is recommended when a rate of febrile neutropenia (FN) higher than 20% is expected without the use of CSF or when additional risk factors for neutropenia exist; therapeutic use of CSF is recommended in order to treat FN episodes but not to treat afebrile neutropenic episodes. In addition, the use of CSF is considered effective when used to mobilise stem cells before high-dose chemotherapy and when used for chemotherapy schedule optimisation in dose-dense and in dose-intense regimens.